Datametrex Increasing Weekly COVID Testing to 300% Upon Request

Toronto, Ontario--(January 11, 2022) - Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTCQB: DTMXF) (the "Company" or "Datametrex") is pleased to announce that the Company is requested by its film and television production companies to increase weekly testing to 300%.

The Company is requested to test on 24-hour rotation effective immediately, instead of the previous 72-hours rotation, due to the surging Omicron SARS-CoV-2 variant (B.1.1.529) numbers.

In the third quarter of 2021, the Company administered over 67,500 tests to 41 production companies: 2 in Montreal, 11 in Toronto and 28 in Vancouver.

"The company is pleased to be able to accommodate the need from the film and production companies. With 24-hour Covid-19 testing rotations, we anticipate a significant increase in revenue in the COVID-19 business," said Marshall Gunter, CEO of the Company.

"With the new Omicron variants spreading, management feels that continued testing will be necessary for the foreseeable future as part of the answer to keep people safe and sound," said Andrew Ryu, Chairman of the Company.

About Datametrex

Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex's mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain.

For additional information on Datametrex and other corporate information, please visit the Company's website at www.datametrex.com.

For further information, please contact:

Andrew Ryu - Chairman

Marshall Gunter - CEO Phone: (514) 295-2300 Email: mgunter@datametrex.com

Neither the TSX Venture Exchange nor it's Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements:

All statements included in this press release that address activities, events, or developments that the Company expects, believes, or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections, and other forward-looking statements will prove inaccurate, certain of which are beyond the Company's control. In particular, there is no guarantee that the parties will successfully negotiate and enter into a definitive agreement on mutually acceptable terms or complete the Transaction in the manner contemplated herein, if at all, that the due diligence of any of the parties will be satisfactory, or that the parties will obtain any required board, shareholder, third-party and/or regulatory or other governmental approvals, if any. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not undertake to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.

###